The stock is likely to trade down on the EPS miss and widening losses. Key catalysts remain the ReMEDy2 interim analysis in 4Q 2026 and preeclampsia data readouts; no near-term financial inflection.
Price Chart
Executive Summary
DiaMedica reported Q1 2026 EPS of -$0.19, missing consensus of -$0.17 by 11.8%. Net loss widened to $10.0M from $7.7M a year ago on higher R&D costs, with cash burn increasing. Operating cash flow was -$9.1M vs -$7.1M. No financial guidance was provided.
Key Financial Metrics
Key Facts
- EPS of -$0.19 missed consensus of -$0.17 by 11.8%
- Net loss widened to $10.0M vs $7.7M YoY
- Cash and investments declined to $51.3M from $59.9M at year-end
- Operating cash flow worsened to -$9.1M from -$7.1M
- No revenue or guidance provided
Financial Impact
EPS miss of $0.02 per share; net loss increased 30% YoY
Risk Factors
- Continued cash burn exceeding expectations
- Clinical trial delays or negative data
- Dilution risk from future capital raises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-015218 |
| Document: dmtp20260506_8k.htm | 0001437749-26-015218 |
| Document: 0001437749-26-015218-index-headers.html | 0001437749-26-015218 |
| Document: 0001437749-26-015218-index.html | 0001437749-26-015218 |
| Document: 0001437749-26-015218.txt | 0001437749-26-015218 |
| 8-K Data (Synthetic) | 0001437749-26-015218 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 10w ago | Institutional Cluster | $6.62 $6.53 | ▼ −1.36% | ▲ +0.62% | $8.74 (+32.02%) |
Aug 10, 2026 11w ago | 8-K | $6.87 $6.59 | ▼ −4.08% | ▼ −3.02% | $8.74 (+27.22%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.46 $7.71 | ▲ +41.21% | ▲ +39.32% | $8.74 (+60.07%) |
May 6, 2026 24w ago | 8-K | $6.53 $5.65 | ▲ +13.48% | ▲ +16.61% | $8.74 (−33.84%) |
Apr 1, 2026 29w ago | DEFA14A | $6.48 $6.05 | ▼ −6.64% | ▼ −16.51% | $8.74 (+34.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers